Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis by Hyo Bae et al.
Bae et al. Journal of Ovarian Research 2014, 7:41
http://www.ovarianresearch.com/content/7/1/41RESEARCH Open AccessObesity and epithelial ovarian cancer survival: a
systematic review and meta-analysis
Hyo Sook Bae1, Hyun Jung Kim2, Jin Hwa Hong1, Jae Kwan Lee1, Nak Woo Lee1 and Jae Yun Song1*Abstract
Background: Studies on the association between obesity and ovarian cancer survival have had conflicting results.
We reviewed and quantitatively summarized the existing evidence, exploring potentially important sources of
variability, such as the timing of body mass index (BMI) assessment, BMI cut points, references used in multivariate
analysis, and ovarian cancer stage.
Methods: Eligible studies were searched using MEDLINE (PubMed), EMBASE, and Cochrane Central Register of
Controlled Trials, relevant bibliographies were manually reviewed for additional studies. Adjusted hazard ratios (HRs)
from individual studies were pooled using a random effects model.
Results: 17 cohort studies of 929 screened articles were included in the final analysis. Obesity in early adulthood
and obesity 5 years before ovarian cancer diagnosis were associated with poor patient survival (early adulthood:
pooled HR 1.67; 95% CI 1.29-2.16; 5 years prediagnosis: pooled HR 1.35; 95% CI 1.03-1.76). However, the results for
obesity at diagnosis depended on whether BMI was analyzed as a categorical or continuous variable. Analysis of
obesity with BMI as a categorical variable did not affect ovarian cancer prognosis (pooled HR 1.07; 95% CI 0.95-1.21);
obesity with BMI as a continuous variable showed slightly poorer survival with each incremental increase in BMI
(pooled HR 1.02; 95% CI 1.01-1.04).
Conclusions: Obesity 5 years before ovarian cancer diagnosis and obesity at a young age were associated with
poor prognosis. The association between obesity at diagnosis and survival of ovarian cancer patients still remains
equivocal. BMI at diagnosis cannot be a prognostic factor for the survival of ovarian cancer patients. Further
well-designed studies are needed to elucidate the variety effect of obesity on the survival of ovarian cancer
patients.
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Ovarian cancer is highly fatal gynecological cancer. It is
the fifth leading cause of cancer mortality in women with
14,030 deaths each year in the United States [1]. Obesity is
a rising health problem worldwide with an increasing
population of obese people and direct links between
obesity and multiple morbidities. Among gynecological
cancers, hormone-related cancers such as endometrial
cancer and breast cancer are related to obesity [2].
Some epidemiological studies report that obesity is re-
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unless otherwise stated.However, results on the relationship between epithelial
ovarian cancer and obesity are conflicting. Recently,
Pavelka et al. reported that obesity affects ovarian cancer
mortality by influencing tumor biology [4]. However,
many studies report no significant change in survival ac-
cording to body mass index (BMI) [5,6]. Most ovarian
cancer patients require an operation and toxic chemother-
apy that can negatively affect their health. Furthermore,
advanced ovarian cancer patients are frequently cachectic,
with ascites that affects BMI but is not true body mass.
Therefore, whether obesity has a true adverse effect on
outcomes of ovarian cancer patients is unknown.
Two studies included a meta-analysis that reported the
relationship between obesity and ovarian cancer survival.
Protani et al., using 2007 data, reported that women. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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slightly worse survival than nonobese women [7]. How-
ever, the association was valid only for studies that in-
cluded women with BMI ≥30. Yang et al., using 2010 data,
reported that obesity in early adulthood is related to
higher mortality among patients with ovarian cancer [8].
However, only studies using BMI as a categorical variable
were included.
In this study, we reviewed the current literature for
an association between obesity and survival of women
with ovarian cancer. We conducted a comprehensive
meta-analysis to determine the impact of obesity as a
risk factor on the prognosis of ovarian cancer, analyzing
the timing of BMI assessment and the methods used to
analyze BMI as a variable.Figure 1 Flow diagram.Methods
Search strategy
This systematic review and meta-analysis were conducted
according to the Meta-analysis of Observational Studies
in Epidemiology (MOOSE) guidelines [9]. A systematic
search to June 2013 of MEDLINE (PubMed), EMBASE
and Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library was conducted to
identify eligible studies on the association between obesity
and survival in women with ovarian cancer. Keywords
were: (obesity OR overweight OR “body mass index” OR
“body size” OR “body weight”) AND (“ovarian cancer” OR
“ovarian neoplasm” OR “ovarian malignancy”) AND (sur-
vival analysis OR survival rate OR survival OR death OR
mortality OR morbidity OR prognosis). The reference lists
Table 1 Characteristics of studies
Study Country N Years of
diagnosis
Follow-up, yr Stage Age, yr Timing of BMI
measurement
BMI category Adjustment variables
Min Zhang et al. China 207 1999-2000 Minimum, 3 all stages 1. at diagnosis BMI < 20.0 Age, stage, grade, ascites, residual lesions,
chemotherapy, total energy intake,
menopausal statusMean alive, 46.7 2. 5 year ago 20.0 ≤ BMI≤ 22.4
Mean dead, 51.6 3. at age 21 y 22.5 ≤ BMI≤ 24.9
25.0 ≤ BMI
Joanne Kotsopoulos et al. Canada 1423 1995-2004 mean 7.4 all stages under, 50.75 5 years prior to
diagnosis
BMI < 18.5 Age at diagnosis, BRCA mutation status,
stage and histologic subtype
range, 0.59-15.72
normal, 56.23 18.5 ≤ BMI≤ 25
overweight,
57.84
25 ≤ BMI≤ 30
obese, 57.78 30 ≤ BMI
Yang Zhou et al. USA 388 1998-2003 all: 9.28 ± 8.68 all stages Median, 58.6 1. during 20s BMI < 25 Age, stage, histology, education, oral
contraceptive use, menopausal status and
HRT use, parity, age at first birth, family
history of ovarian cancer, time from
ovarian cancer diagnosis to study
enrollment
BMI≥ 25




BMI≥ 25: 9.95 ± 9.38 3. 9 months
post-chemotherapy




635 1993-1995 Range, 50-74 all stages 50-74 1. Age 18 BMI < 18.5 Age at diagnosis, FIGO stage and WHO
grade of differentiation
18.5 ≤ BMI≤ 25
2. 1 year prior
to ovarian
cancer diagnosis
25 ≤ BMI≤ 30
30 ≤ BMI
I. SKI’RNISDO’ TTIR et al. Sweden 635 1975-2004 Mean, 6.8 I,II Mean 60.1 at the start of the
adjuvant therapy
BMI < 18.5 Stage, grade, histology
18.5 ≤ BMI≤ 25
25 ≤ BMI≤ 30
30 ≤ BMIRange, 1.6-17.8
Anette Kjærbye-
Thygesen et al.
Denmark 295 1994-1999 Median, 7.3 III Range, 35-79 1. BMI age at
20-29y
BMI < 18.5 Age, radicality of surgery, histology,
platinum-based chemotherapy, smoking
status, continuous BMI 5 years before
diagnosis
18.5 ≤ BMI≤ 24.9
Range, 5.4-9.5 2. BMI 5years before
diagnosis
25.0 ≤ BMI









Age at diagnosis, stage at diagnosis,
histologic type, oral contraceptive use,
parity, menopausal status, presence of any
other chronic conditions including
diabetes, high blood pressure, chronic
kidney disease, gallbladder disease,
2. BMI at age 18,
3. weight change

















Table 1 Characteristics of studies (Continued)
myocardial infarction, heart disease, high
cholesterol, paralysis, or stroke
Kirsten B. Moysich et al. USA 395 1982-1998 NA (≥9) all stages mean(SD) self-reported BMI < 18.5 age at diagnosis, FIGO stage
alive: 47.5(14.1) 1. current height
and weight
18.5 ≤ BMI≤ 25




Sweden 446 1994-2003 Mean, 3.9 all stages Mean, 62.5 at the start of the BMI ≤25 Age, stage, histology
Range, 0-12.3 range, 25-91 adjuvant therapy BMI > 25
James C. Pavelka et al. USA 149 1996-2003 Not stated III-IV Range, 18-79 first postoperative
visit
BMI < 18.5 nil
18.5 ≤ BMI≤ 25
25 ≤ BMI≤ 30
30 < BMI
Schlumbrecht, M. USA 127 2002-2007 mean, 3.1 (0.3-7.2) not
stated
not stated not stated BMI < 18.5 not stated
18.5 ≤ BMI≤ 25
25 ≤ BMI≤ 30
30 < BMI
Dolecek, T.A. et al. USA 341 1994-1998 Not stated I-IV Range, 18-74 Self-reported BMI at
diagnosis
BMI < 18.5 Age, race, stage, grade, residual lesions,
smoking status, oral contraceptive use, parity
18.5 ≤ BMI≤ 25
25 ≤ BMI≤ 30
30 ≤ BMI
Fotopoulou, C. et al. Germany 306 2000-2010 11.7 months
(0.1-62.9)
I-IV 58(18–92) Not stated BMI < 25 Residual tumor, grade, positive lymph
node status, age, FIGO stage, Ascites, IMO
level 2/3 involvement, nonserous histology,
distant metastasis
BMI≥ 25
Lamkin, D.M. et al. USA 74 2001-2005 Not stated I-IV 62(33–87) Not stated BMI as continuous
variable
None (univariate analysis)
Nagle, C.M. et al. Australia 609 1990-1993 Median 7.3 yrs
(5–8.3)
I-IV 18-79 Prior to illness BMI <22.2 FIGO stage, age, grade, total energy intake
(Kilocalories), BMI, residual, ascites, smoking
status, parity and length of OCP use22.2-25.8
BMI > 25.8
Schlumbrecht, M.P. et al. USA 194 1977-2009 Median f/u 60.9
months (1–383)
I-IV 44.9(14–79) 8 wks after primary
surgical intervention
BMI <25 Stage, Taxane, Current alcohol use, year of
diagnosis, current smoker, age at diagnosis,
hormone tx after adjuvant ctx25 ≤ BMI < 30
30 ≤ BMI < 35
35 ≤ BMI
Schildkraut, J.M. et al. USA 197 1980-1982 Not stated I-IV 20-54 At diagnosis BMI > 27.9 None (univariate analysis)
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scanned to identify additional studies for inclusion.
Study selection and data extraction
Eligibility criteria for inclusion in the systematic review
were (1) original data examining the association between
obesity and survival in a cohort of patients with ovarian
cancer, and (2) outcome measures reported as adjusted
hazard ratios (HRs). Two authors (H-S.B. and J-Y.S.) inde-
pendently evaluated the eligibility of all studies retrieved
from the databases. For all eligible studies, information
was extracted on study design, country, year of diagnosis,
number of years of follow up, participant ages, tumor
stage, BMI definitions and categories, timing of BMI
measurement, median patient survival, effect estimates,
and variables included in analysis adjustment.
Statistical analysis
HR estimates were pooled using random-effects analysis
using the method of DerSimonian and Laird, and het-
erogeneity across studies was assessed using the I2 statis-
tic from Higgins and Thompson, which measures the
percentage of total variation across studies [10,11].
Pooled HR with 95% CIs, were determined using ad-
justed HRs and CIs reported in the articles or obtained
from the authors. When several HR values were given in
an article, the value adjusted for most confounders was
used. Subgroup analyses were by BMI category, BMI
measurement timing, and BMI group, which was the ref-
erence for regression analysis. In four studies, the effect
of obesity on ovarian cancer survival was reported with
BMI as a continuous variable; we pooled those studies
separately [4,12-14]. Publication bias was assessed byStudy or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.21, df = 2 (P = 0.90); I² = 0%
Test for overall effect: Z = 3.94 (P < 0.0001)





Heterogeneity: Tau² = 0.04; Chi² = 5.36, df = 2 (P = 0.07); I² = 63%
Test for overall effect: Z = 2.17 (P = 0.03)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 7.72, df = 5 (P = 0.17); I² = 35%
Test for overall effect: Z = 4.14 (P < 0.0001)

























Figure 2 Obesity before diagnosis. (Note: BMI ≥ 25–30).examining funnel plot asymmetry. We assessed the quality
of included studies using the Newcastle-Ottawa scale [15].
Quality scores were calculated based on three major
components: (1) selection of groups to study, (2) com-
parability, and (3) assessment of outcome or exposure.
The quality scores of included studies were similar, ran-
ging from 5 to 8 (Additional files 1 and 2) with a max-
imum score of 9, representing the highest methodological
quality. Sensitivity analyses determined differences in
study design, sample size, study quality grade, and diag-
nostic criteria for obesity. Statistical analyses were con-
ducted using Review Manager, ver5.2 (Nordic Cochrane
Center, Copenhagen, Denmark).
Results
Identification of relevant studies
A total of 929 citations were found by searching MEDLINE,
EMBASE and CENTRAL; 804 articles were excluded
during title review and 101 articles were excluded dur-
ing abstract review. Thus, 24 articles underwent full text
review, and 17 cohort studies were included in the final
meta-analysis (Figure 1, Table 1). General characteristics
of the included studies are in Table 1.
Meta-analysis
Association between obesity before diagnosis and
ovarian cancer patient survival
Four studies reported HRs related to obesity before diag-
nosis. Three studies that included BMI in adolescence in
analyses were pooled, yielding a summary HR estimate of
1.67 (95% CI, 1.29-2.16). Three studies analyzing BMI 5
years before diagnosis showed similar results (HR, 1.35;
95% CI, 1.03-1.76) (Figure 2).%










Hazard Ratio Hazard Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours [experimental] Favours [control]
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cancer patient survival
The selected studies that included BMI at diagnosis in
analyses had substantial interstudy heterogeneity in the
BMI cutoff used to define obesity, the reference group for
analysis; and the form of the BMI variable, continuous
or categorical. Eight studies used data on obesity at
diagnosis and survival of ovarian cancer patients using a
normal weight group as the reference group. Pooling
the data from the eight studies resulted in a summary
HR estimate of 1.11 (95% CI, 0.97-1.27). Subgroup ana-
lysis of two studies with BMI ≥ 25 as the cutoff value for
obesity yielded a summary HR estimate of 0.97 (95% CI,
0.72-1.30). Analysis of six studies with BMI >30 as
obese yielded a summary HR estimate of 1.15 (95% CI,
0.98-1.38) (Figure 3). Five studies used a low-weight
group as a reference group in analyses. Pooling these
five cohort studies yielded a summary HR of 0.96 (95%











Heterogeneity: Tau² = 0.00; Chi² = 7.23, df = 7 (P = 0.41); I² = 3%





Heterogeneity: Tau² = 0.00; Chi² = 1.00, df = 1 (P = 0.32); I² = 0%









Heterogeneity: Tau² = 0.00; Chi² = 5.23, df = 5 (P = 0.39); I² = 4%

























































Figure 3 Obesity at diagnosis (normal weight as reference).continuous variable. The pooled summary HR of these
studies was 1.02 (95% CI, 1.01-1.04) per incremental
BMI unit (Figure 5).Discussion
For almost every health condition, obese patients show
poorer outcome than non-obese patients because obese
patients generally have more comorbidities such as hyper-
tension, diabetes, and MI [16,17]. Nevertheless, no conclu-
sive relationship has been established between obesity and
ovarian cancer patient survival.
In this meta-analysis, we investigated the association
between obesity before diagnosis (at 5 years before diag-
nosis and at a young age) and ovarian cancer patient
survival. The association between obesity at the time of
diagnosis and ovarian cancer survival was weaker than
the association between BMI evaluated before diagnosis
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Heterogeneity: Tau² = 0.00; Chi² = 1.94, df = 4 (P = 0.75); I² = 0%
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Figure 4 Obesity at diagnosis (low-weight as reference).
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on the association between obesity and ovarian cancer sur-
vival. Although two meta-analyses were previously pub-
lished, our results are noteworthy because some of our
results differ from previous studies and some are more re-
liable because of strictly structured subgroup analysis.
Obesity at a young age and before ovarian cancer diag-
nosis appeared to be related to poor cancer outcome. Yang
et al. reported similar results, showing a possible relation-
ship between obesity in early adulthood and higher mor-
tality [8]. However, two previous meta-analyses reported
different results about the association between BMI at
diagnosis and ovarian cancer survival. Protani et al. re-
ported a pooled HR of 1.13 (95% CI; 0.81-1.57) for BMI
at diagnosis and ovarian cancer survival with a slightly
stronger association in studies that defined only women
with BMI ≥ 30 as obese. Protani et al. concluded that
women with ovarian cancer who are obese have slightly
worse survival outcomes than nonobese women [7].
Our results are similar to Yang et al., which reported no
significant relationship between prognosis and obesity
at diagnosis [8]. Our study includes more cohort studies
than Yang et al.
Interestingly, our study showed two different results
in the association between BMI at diagnosis and ovarian
cancer survival. Although only four studies were included
in our meta-analysis, BMI as a continuous variable wasFigure 5 BMI as continuous variable.related to poor ovarian cancer outcome (Figure 5). The
HR of 1.02 per incremental BMI unit was not clinically
insignificant because this HR estimate suggest a 10%
increase in mortality with 5-unit increase in BMI.
We support the hypothesis that obesity has adverse ef-
fects on the mortality in the general population [16,17].
In our study, the relationship between obesity before
diagnosis and ovarian cancer patient mortality was simi-
lar to results on the general population. We suggest that
the weak relationship between obesity at diagnosis and
ovarian cancer survival was due to some factors of ovar-
ian cancer patients that interfered with or weakened the
potential adverse effects of obesity on health.
We propose several reasons for the weak relationship
between obesity at diagnosis and ovarian cancer survival.
First, BMI is not an appropriate measure for evaluating
the degree of obesity in ovarian cancer patients because
they often have ascites or cachexia [18,19]. Second, obese
or overweight patients with ovarian cancer might endure
toxic chemotherapy better than nonobese patients. Third,
an unknown action of obesity might improve ovarian can-
cer outcomes.
Although we tried to overcome inference by confounding
factors, primary observational cohort studies have inherent
limitations. Additional well-designed epidemiological and
laboratory studies could reveal the true effects of obesity on
ovarian cancer survival.
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The results of our meta-analysis suggested that obesity
before cancer diagnosis was associated with poor ovarian
cancer patient survival. However, the adverse effect of
obesity on ovarian cancer survival was still equivocal for
BMI measured at the time of diagnosis. BMI at diagnosis
cannot be a prognostic factor for the survival of ovarian
cancer patients. Further well-designed studies are needed
to elucidate the variety effect of obesity on the survival of
ovarian cancer patients.
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